Evidence map›Paper›PMID 33039499›Full record

ArticleThe Journal of infection2021

Effect of administering subsequent immune checkpoint inhibition in cancer patients with prior COVID-19 infection.

Jianping Bi, Sheng Wang, Yajie Wang, Dongqin Yang, Vivek Verma, Jing Huang, Guang Han

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Jianping BiDepartment of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, zhuodaoquan South Road No.116, Wuhan, Hubei 430079, China.
Sheng WangDepartment of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, zhuodaoquan South Road No.116, Wuhan, Hubei 430079, China.
Yajie WangDepartment of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, zhuodaoquan South Road No.116, Wuhan, Hubei 430079, China.
Dongqin YangDepartment of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, zhuodaoquan South Road No.116, Wuhan, Hubei 430079, China.
Vivek VermaDepartment of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, zhuodaoquan South Road No.116, Wuhan, Hubei 430079, China.
Jing HuangDepartment of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, zhuodaoquan South Road No.116, Wuhan, Hubei 430079, China.
Guang HanDepartment of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, zhuodaoquan South Road No.116, Wuhan, Hubei 430079, China. Electronic address: hg7913@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19NeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapyLaboratoriesSARS-CoV-2Immune Checkpoint Inhibitors

Identifiers

PMID33039499
PMCPMC7543776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.